Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BENDAMUSTINE Cause Diffuse large b-cell lymphoma refractory? 61 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 61 reports of Diffuse large b-cell lymphoma refractory have been filed in association with BENDAMUSTINE (VIVIMUSTA). This represents 0.3% of all adverse event reports for BENDAMUSTINE.

61
Reports of Diffuse large b-cell lymphoma refractory with BENDAMUSTINE
0.3%
of all BENDAMUSTINE reports
7
Deaths
2
Hospitalizations

How Dangerous Is Diffuse large b-cell lymphoma refractory From BENDAMUSTINE?

Of the 61 reports, 7 (11.5%) resulted in death, 2 (3.3%) required hospitalization.

Is Diffuse large b-cell lymphoma refractory Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BENDAMUSTINE. However, 61 reports have been filed with the FAERS database.

What Other Side Effects Does BENDAMUSTINE Cause?

Off label use (2,578) Disease progression (2,456) Pyrexia (1,322) Neutropenia (1,256) Drug ineffective (1,135) Febrile neutropenia (1,005) Pneumonia (975) Thrombocytopenia (967) Covid-19 (892) Anaemia (817)

What Other Drugs Cause Diffuse large b-cell lymphoma refractory?

RITUXIMAB (461) CYCLOPHOSPHAMIDE (360) DOXORUBICIN (345) VINCRISTINE (331) ETOPOSIDE (244) PREDNISONE (214) EPCORITAMAB-BYSP (198) CYTARABINE (193) DEXAMETHASONE (170) CISPLATIN (156)

Which BENDAMUSTINE Alternatives Have Lower Diffuse large b-cell lymphoma refractory Risk?

BENDAMUSTINE vs BENDROFLUMETHIAZIDE BENDAMUSTINE vs BENIDIPINE BENDAMUSTINE vs BENLYSTA BENDAMUSTINE vs BENRALIZUMAB BENDAMUSTINE vs BENSERAZIDE

Related Pages

BENDAMUSTINE Full Profile All Diffuse large b-cell lymphoma refractory Reports All Drugs Causing Diffuse large b-cell lymphoma refractory BENDAMUSTINE Demographics